Results 61 to 70 of about 37,793 (186)
This report is associated with an ongoing coronavirus outbreak. We selected Remdesivir (used in the treatment of Ebola) and Aspirochlorine (a natural product found in Aspergillus oryzae), and their binding to specific peptide sequences of the coronavirus
Yousra, Abdel-Mottaleb +1 more
core +1 more source
Due to the 2019 pandemic caused because to the coronavirus disease (Covid-19) has led to the investigation of different drugs for their efficacy and therapeutic benefits for people suffering from the Covid-19 illness because of its high prevalence, easy ...
Ismath Bano, Nazakath Shaista Fatima, Bushra Sereen, Nishath Fatima, Dr. Mohammed Ashfaq Hussain*
core +1 more source
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara +20 more
wiley +1 more source
COVID-19, a disease caused by a new strain of coronavirus (SARS-CoV-2) originating from Wuhan, China, has now spread around the world, triggering a global pandemic, leaving the public eagerly awaiting the development of a specific medicine and vaccine ...
Koichiro, Kato +2 more
core +1 more source
Remdesivir: from Ebola to COVID-19
Human coronaviruses (HCoV) were discovered in the 1960s and were originally thought to cause only mild upper respiratory tract diseases in immunocompetent hosts.
Maria Gabriella Santoro
core +1 more source
Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice
Pulmonary fibrosis is a known sequela of severe or persistent lung damage. Existing clinical, imaging and autopsy studies have shown that the lungs exhibit a pathological pulmonary fibrosis phenotype after infection with coronaviruses, including severe ...
Xiaohe Li +17 more
doaj +1 more source
Longitudinal 1H and 129Xe Lung MRI in Patients With Post‐COVID Residual Lung Abnormalities
ABSTRACT Background It is unclear how lung function may recover in patients with residual lung abnormalities (RLAs) following COVID‐19 pneumonia. Purpose To evaluate lung function trends over time in patients with RLAs following hospitalization due to COVID‐19. Study Type Prospective, multicenter longitudinal cohort study.
Laura C. Saunders +41 more
wiley +1 more source
Remdesivir for the treatment of COVID‐19
BACKGROUND: Remdesivir is an antiviral medicine with properties to inhibit viral replication of SARS‐CoV‐2. Positive results from early studies attracted media attention and led to emergency use authorisation of remdesivir in COVID‐19.
Benstöm, Carina +10 more
core +1 more source
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009.
Mohd. Imran +3 more
doaj +1 more source
This cohort study of 395 children (mean age 7 years) with SARS‐CoV‐2 demonstrates that measuring levels of miR‐296‐5p in saliva at the time of initial clinical presentation may aid the prognosis of severe symptoms. ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may impact immune‐related micro ribonucleic acids (miRNAs).
Steven D. Hicks +7 more
wiley +1 more source

